XBIT — XBiotech Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1626878 ·
Last close
$1.78
Market Cap
$54.27M
52W High
$2.73
52W Low
$1.78
ADV30
84,173
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -5,319,000 | -4,460,000 | 128,611,000 | 105,037,000 | 4,546,000 |
| Jun 2026 | 0 | — | -6,146,000 | -6,728,000 | 133,651,000 | 109,528,000 | 5,190,000 |
| Mar 2026 | 0 | — | -6,274,000 | -5,505,000 | 139,836,000 | 115,459,000 | 4,819,000 |
| Dec 2025 | 0 | — | -29,755,000 | -26,892,000 | 150,082,000 | 125,551,000 | 9,732,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-40,695,000
Investing CF
$-139,000
Financing CF
$0
CapEx
$-289,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.66
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-148,610,000
Inventory
—
Receivables
$291,000
ST Investments
—
EBIT TTM
$-44,860,000
Pretax Income TTM
$-44,860,000
Interest Exp TTM
$0
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -55,685,000 | -45,540,000 | 150,082,000 | 9,732,000 | 140,350,000 | -39,920,000 |
| Dec 2024 | 0 | -42,471,000 | -38,531,000 | 199,093,000 | 16,825,000 | 182,268,000 | -30,963,000 |
| Dec 2023 | 0 | -37,510,000 | -24,557,000 | 226,615,000 | 7,769,000 | 218,846,000 | -18,725,000 |
| Dec 2022 | 4,010,000 | -34,490,000 | -32,900,000 | 246,103,000 | 5,701,000 | 240,402,000 | -14,824,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$8,013,000
NetIncome TTM
$-45,133,000
OpCashFlow TTM
—
Assets (Latest)
$133,651,000
Forward EPS
$0.13
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.73 · call volume: 20 · put volume: 10
Expected Move to 2027-01-15:
±$0.80
(46.24%) —
implied range
$0.93 –
$2.53
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QUCY | Quantum Cyber N.V. | $54.38M | $0.62 | — |
| INCR | Intercure Ltd. | $54.16M | $3.61 | — |
| VRCA | Verrica Pharmaceuticals Inc. | $53.94M | $3.14 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $53.70M | $0.28 | — |
| IBO | IMPACT BIOMEDICAL INC. | $53.31M | $6.17 | — |
News headlines (Yahoo Finance, 1h cache)
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
2026-10-19 13:00 · Yahoo
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
2026-06-15 13:00 · Yahoo
XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers
2026-10-23 13:17 · Yahoo
3 Promising Penny Stocks With Market Caps Over $30M
2025-12-19 18:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.